aTyr Pharma

ATYR PHARMA INC

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

4 Stocks You Need To Buy Now for Consistent Profits—Here’s Why Analysts Love Them

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ATYR

ENGN

ESLA

SHLS

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts Pick 4 Stocks Poised for Growth, Including Tech Giants Microsoft And Meta

NNOX

TOST

TTAN

This Toast Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Penny,Stock,Investments,Taking,Off,Concept

Long Ideas

Penny Stocks

Insider Trades

Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying

aTyr Pharma Inc

Press Releases

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Biotech

General

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

Health Care

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

Earnings

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Absci

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Astria Therapeutics

Aura Biosciences

Candel Therapeutics

Cidara Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Emergent BioSolutions

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prime Medicine

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Solid Biosciences

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

2seventy bio

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Verastem

XOMA Royalty

HC Wainwright & Co.

Leerink Partners

Wells Fargo

Jefferies

RBC Capital

Comments

aTyr Pharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga